Isentress Related Published Studies
Well-designed clinical trials related to Isentress (Raltegravir)
Sustained efficacy and safety of raltegravir after 5 years of combination
antiretroviral therapy as initial treatment of HIV-1 infection: final results of
a randomized, controlled, phase II study (Protocol 004). [2012]
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [2011.09]
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). [2011.07.31]
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. [2011.07.17]
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. [2011.04.01]
Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. [2011.04]
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. [2011.04]
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. [2010.12]
Effect of raltegravir on the pharmacokinetics of methadone. [2010.12]
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. [2010.11]
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. [2010.09.24]
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. [2010.09.01]
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. [2010.09.01]
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). [2010.09]
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. [2010.09]
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. [2010.09]
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. [2010.08.10]
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. [2010.07.17]
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. [2010.07.17]
Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. [2010.07]
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. [2010.04.01]
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. [2010.02.15]
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. [2010.02]
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. [2010.01.30]
The effect of raltegravir intensification on low-level residual viremia in
HIV-infected patients on antiretroviral therapy: a randomized controlled trial. [2010]
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients:
96-week efficacy, durability, subgroup, safety, and metabolic analyses. [2010]
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in
patients with limited treatment options in a Phase II study. [2010]
Long-term efficacy and safety of Raltegravir combined with optimized background
therapy in treatment-experienced patients with drug-resistant HIV infection: week
96 results of the BENCHMRK 1 and 2 Phase III trials. [2010]
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. [2009.11.01]
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. [2009.10.15]
The effect of raltegravir on the glucuronidation of lamotrigine. [2009.10]
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. [2009.09.05]
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. [2008.12]
Lack of a significant drug interaction between raltegravir and tenofovir. [2008.09]
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. [2008.07.24]
Raltegravir with optimized background therapy for resistant HIV-1 infection. [2008.07.24]
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. [2008.07.01]
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. [2008.02]
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. [2008.02]
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. [2007.11.12]
Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study. [2007.10.01]
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. [2007.04.14]
Well-designed clinical trials possibly related to Isentress (Raltegravir)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. [2006.12.15]
Other research related to Isentress (Raltegravir)
A randomized controlled trial assessing the effects of raltegravir
intensification on endothelial function in treated HIV infection. [2012]
A randomized trial of Raltegravir replacement for protease inhibitor or
non-nucleoside reverse transcriptase inhibitor in HIV-infected women with
lipohypertrophy. [2012]
Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized
clinical trial of raltegravir versus non-nucleoside reverse transcriptase
inhibitor-based regimens. [2012]
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir
plus atazanavir strategies in ART-treated adults. [2012]
No effect of a single supratherapeutic dose of lersivirine, a next-generation
nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in
healthy subjects. [2012]
No effect of raltegravir intensification on viral replication markers in the
blood of HIV-1-infected patients receiving antiretroviral therapy. [2012]
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. [2011.07]
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. [2011.07]
Raltegravir in pregnancy: a case series presentation. [2011.06]
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. [2011.06]
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. [2011.06]
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. [2011.06]
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients. [2011.05]
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. [2011.05]
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. [2011.05]
Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. [2011.03.13]
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. [2011.03]
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. [2011.03]
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. [2011.03]
Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. [2011.03]
Long-term safety from the raltegravir clinical development program. [2011.01.01]
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. [2011]
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and
raltegravir once and twice daily in HIV-infected individuals. [2011]
Pharmacokinetics and safety of the co-administration of the antiretroviral
raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. [2011]
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. [2010.12.21]
Emergence of raltegravir-resistant HIV-1 in the central nervous system. [2010.12]
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. [2010.11]
Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways. [2010.08]
Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease. [2010.07]
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. [2010.07]
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. [2010.06]
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. [2010.05]
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. [2010.05]
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. [2010.05]
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. [2010.04]
Raltegravir: in treatment-naive patients with HIV-1 infection. [2010.03.26]
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. [2010.03.16]
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. [2010.03.15]
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. [2010.03]
Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. [2010.03]
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. [2010.03]
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. [2010.02.26]
Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. [2010.02]
New therapeutic strategies for raltegravir. [2010.02]
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. [2010]
Impact on health-related quality of life of a switch from enfuvirtide to
raltegravir among multidrug-resistant HIV-1-infected patients: a randomized
open-label trial (EASIER-ANRS 138). [2010]
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in
HIV-uninfected adults. [2010]
Effect of raltegravir on the pharmacokinetics of methadone. [2010]
HIV resistance to raltegravir. [2009.11.24]
Raltegravir use in special populations. [2009.11.24]
Raltegravir in treatment naive patients. [2009.11.24]
Drug-drug interactions with raltegravir. [2009.11.24]
Raltegravir: molecular basis of its mechanism of action. [2009.11.24]
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. [2009.11]
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. [2009.08.01]
Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. [2009.07]
Evolution of raltegravir resistance during therapy. [2009.07]
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. [2009.07]
|
